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Abstract
Mixed P. falciparum/P. vivax infections are common in southeast Asia. When patients with P. falciparum malaria are treated
and followed for several weeks, a significant proportion will develop P. vivax malaria. In a combined analysis of 243 patients
recruited to two malaria treatment trials in western Cambodia, 20/43 (47%) of those with P. falciparum gametocytes on
admission developed P. vivax malaria by Day 28 of follow-up. The presence of Pf gametocytes on an initial blood smear was
associated with a 3.5-fold greater rate of vivax parasitemia post-treatment (IRR=3.5, 95% CI 2.0–6.0, p,0.001). The
increased rate of post-treatment P. vivax infection persisted when correlates of exposure and immunity such as a history of
malaria, male gender, and age were controlled for (IRR=3.0, 95% CI 1.9–4.7, p,0.001). Polymerase chain reaction (PCR)
confirmed that only a low proportion of subjects (5/55 or 9.1%) who developed vivax during follow-up had detectable Pv
parasites in the peripheral blood at baseline. Molecular detection of falciparum gametocytes by reverse transcriptase PCR in
a subset of patients strengthened the observed association, while PCR detection of Pv parasitemia at follow-up was similar
to microscopy results. These findings suggest that the majority of vivax infections arising after treatment of falciparum
malaria originate from relapsing liver-stage parasites. In settings such as western Cambodia, the presence of both sexual
and asexual forms of P. falciparum on blood smear at presentation with acute falciparum malaria serves as a marker for
possible occult P. vivax coinfection and subsequent relapse. These patients may benefit from empiric treatment with an 8-
aminoquinolone such as primaquine.
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Introduction
Despite prevalence of both P. falciparum and P. vivax in South
and Southeast Asia, Oceania, and parts of South America, mixed
infections of the two species were rarely reported in the past, with
cross-sectional prevalence rates reported at ,5% [1]. The
application of PCR detection of different malaria species has
revealed that mixed infections are actually quite common and
often simply go unrecognized in the field. In Thailand, it is
estimated that 25–50% of malaria infections are mixed P.
falciparum/P. vivax [1–3]. This estimate is based not only on PCR
detection methods, but also on observations from longitudinal
treatment trials conducted in the 1980s in which approximately
one-third of patients treated for apparent P. falciparum mono-
infection developed P. vivax infection within 28 days of treatment
with short half-life antimalarials such as artesunate [4,5]. Since
these patients were removed from malaria endemic areas at
enrollment, development of P. vivax malaria post-treatment
suggested a relapse from a previously unappreciated vivax
infection rather than new infection.
Subsequent antimalarial trials conducted in Southeast Asia and
Papua New Guinea have continued to demonstrate high rates of P.
vivax infection post-treatment, especially when follow-up is
continued beyond the period when the antimalarials used are
expected to maintain efficacious drug levels in the bloodstream
[6,7]. Recently, a study involving 811 patients in Myanmar found
that 35% of those with P. falciparum monoinfection by peripheral
smear developed P. vivax malaria during the 63-day follow-up
period [8]. On the Thai-Burmese border, a retrospective analysis
of 15 years of clinical trial data found that the cumulative 63-day
risk of vivax malaria after Pf mono-infection was 51% following
treatment with rapidly eliminated drugs [9]. These high rates of
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of liver-stage vivax infection with a full course of primaquine (anti-
hypnozoite therapy) in all patients with microscopically confirmed
malaria where both species are endemic [10]. Identifying risk
factors for developing relapse from a liver-stage vivax infection
could help refine such a strategy. We conducted a retrospective
analysis of two malaria treatment trials of uncomplicated
falciparum malaria to examine whether falciparum gametocyte
carriage at presentation is associated with subsequent P. vivax
relapse.
Methods
Clinical studies
Between 2006–2009, two open-label clinical trials were
conducted at the same site in Tasanh, western Cambodia to
investigate reports of emerging artemisinin resistance. In ARC1,
patients with uncomplicated P. falciparum malaria were random-
ized in a 2:1 ratio to receive 7 days of artesunate (4 mg/kg/day) or
quinine (30 mg/kg/day) plus tetracycline (25 mg/kg/day) for 7
days. In ARC2, patients with uncomplicated falciparum malaria
were randomized to receive one of three artesunate dosing
regimens: 2, 4, or 6 mg/kg/day for 7 days. In both studies,
enrollment was limited to otherwise healthy adults with P.
falciparum mono-infection as determined by light microscopy and
with no history of antimalarial use in the 30 days prior to
enrollment. The only difference in inclusion criteria between the
two studies was a minimum parasite density of 1,000 parasites/ml
in ARC2 compared to 100 parasites/ml in ARC1. Written
informed consent was obtained from all study participants prior
to enrollment. Subjects received directly observed therapy over 7
days with thick and thin blood smears prepared every 12 hours in
ARC1 and every 2–6 hours in ARC2 until parasite clearance was
achieved. Both studies recorded temperature every 4 hours, with
fever clearance defined as the first time the patient became afebrile
with absence of fever for the next 24 hours. In ARC1, patients
remained in a study ward for 21 days to prevent reinfection, with
weekly clinical and blood smear assessments on days 7, 14 and 21,
and then returned for one final outpatient follow-up on Day 28. In
ARC2, subjects remained on the study ward for the 7 days of
therapy, then returned weekly until Day 42 for outpatient follow-
up. Further details of these studies have been previously published
[11,12].
Identification of parasite species
Giemsa-stained slides were examined by two microscopists
blinded to each other’s results and to the treatment status of the
study subject. Counts were reported as the number of asexual
parasites and gametocytes per 200 white blood cells seen on the
thick smear. If the thick film exceeded 500 parasites per 200
WBCs, parasites were counted per 2000 RBCs (ARC1) or per
5000 RBCs (ARC2). At least 200 oil immersion fields were
examined on the thick film before a blood smear was considered
negative. The final count was determined by taking the geometric
mean of the two microscopists’ counts. Discordant results were
resolved by a third reference microscopist.
Molecular identification of parasite species was performed on all
admission blood samples (Day 0) from both studies and on weekly
blood samples available in the ARC2 patients to assess for
subpatent mixed infection at baseline and occult parasitemia
during follow-up. This was done using real-time PCR assays
targeting the 18srRNA gene (Schaecher et al. manuscript in
preparation). Briefly, DNA extracted from 200 mLs of EDTA
blood using the QIAampH DNA blood mini kit was diluted down
to a working concentration of 3 ng/ml. Primers and FAM-labeled
MGB probes previously adapted from published protocols were
used for a pan-species Plasmodium assay, a falciparum-specific
assay, and a vivax-specific assay [13]. For each real-time PCR
assay, 6.25 ml of template DNA was added to a reaction mixture
containing 200 nM primers and 100 nM probe for a total reaction
volume of 25 ml. Thus DNA from approximately 1 ml of blood was
assayed in each PCR tube. Cycling conditions for the Applied
Biosystems 7900 system were 50uC for 1 min, 95uC for 10 min,
and 45 cycles of 95uC for 15 s and 60uCo r5 9 uC for 1 min. All
samples were run in triplicate with positive and negative controls
in each reaction plate. A Ct value of 37 cycles was used as the
threshold cutoff for positivity in the Pv assay. Using this Ct value, it
was previously determined that the assay has a limit of detection
for P. vivax of 0.5–5 parasites/ml.
Molecular detection of gametocytes
Reverse transcriptase PCR (RT-PCR) based on the mature
gametocyte marker Pfs25 was used to assess for subpatent carriage
of falciparum gametocytes in admission blood samples from the
patients enrolled in ARC2. RNA purified from 2.5 mLs of whole
blood using the Qiagen PAXgene Blood RNA kit was diluted
down to a working concentration of 50 ng/ml. cDNA synthesis
and nested PCR were then carried out with the Qiagen
OmniscriptH RT kit and Qiagen HotStarTaqH PCR kit and
primers following a previously published protocol [14]. Each RNA
sample was run with an RT-minus control to assess for DNA
contamination. Nested PCR runs contained a 3D7 gDNA positive
control as well as a negative control. PCR products were resolved
by electrophoresis on a 1.5% agarose gel, and the presence or
absence of an approximately 650 bp band representing amplifi-
cation of the Pfs25 transcript was determined using ultraviolet
illumination.
Statistical analysis
Microscopic and clinical data from the two studies were
combined and retrospectively analyzed to determine P. vivax
infection rates and risk factors for the development of post-
treatment vivax malaria. Data was entered into Microsoft Excel
and analyzed with STATA 10.1 (College Station, Texas) and
SPSS 18 (Somers, NY). Clinical characteristics of the patients
enrolled in ARC1 vs. ARC2 as well as those with and without
gametocytes on admission were compared using Pearson Chi-
Square, Mann-Whitney U, Fisher’s exact test, or student’s t-tests
as appropriate. Kaplan Meier analysis was used to visually
compare the incidence of Pv infection over time. Pv incidence
rate (Pv IR) was selected as the measure of frequency to account
for the different lengths of person follow-up between the ARC
trials. Pv IR was calculated as the number of Pv episodes among
any patient over the number of days until a Pv episode or the end
of follow-up. Pv incidence rates were analyzed by ARC study,
study treatment, and clinical variables of interest. Patients who did
not complete study follow-up were not included in the analysis.
A multivariate analysis was conducted to estimate the unbiased
association of gametocytemia on admission and post-treatment
vivax infection. Covariates for the model were selected based on
the univariate analysis and through prior knowledge regarding the
association between gametocytemia and Pv relapse. A Poisson
model with robust standard errors was constructed and the
selection of final covariates was determined through a backwards
elimination process to capture joint effects. Confounding was
assessed by examining the change in estimate for the exposure
when each covariate was individually removed. If the removal of a
covariate changed the estimate by at least 10% it was considered
Gametocytes and vivax Co-Infection
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Covariates that were examined included gametocyte carriage at
admit, study (ARC1 vs. ARC2), presence of anemia, age, male
gender, parasite density, history of malaria, parasite clearance
time, fever clearance time, white blood cell count, and duration of
symptoms.
Ethics
Ethics approval for this study was obtained from the ethics
committees of the Walter Reed Army Institute of Research (Silver
Spring, USA) and the National Ethics Committee for Health
Research (Phnom Penh, Cambodia).
Results
Between October 2006–February 2007 and August 2008–July
2009, 111 and 143 patients with P. falciparum malaria were enrolled
in the ARC1 and ARC2 trials, respectively. Four and 7 patients
were withdrawn or lost to follow-up in the respective studies,
leaving a total of 243 patients who completed 28 or 42-day follow-
up that were included in the analysis.
Clinical characteristics of the two study populations differed in
several ways (Table 1). Due to the minimum 1,000 parasites/ml
inclusion criteria in the later study, patients in ARC2 had
significantly higher baseline parasitemias, with a median parasit-
emia double that in ARC1 (12,748 vs. 6,562 parasites/ml). Patients
in ARC2 were more likely to be male (79% vs. 64%), less
frequently reported a history of malaria in the previous 12 months
(33% vs. 41%), and demonstrated slower parasite and fever
clearance times (median 78 vs. 64 hours and 16 vs. 9 hours,
respectively) than patients in ARC1.
Gametocyte carriage
Falciparum gametocyte carriage at admission was similar in
both studies (Table 1). In the combined analysis, 43/243 (18%) of
patients had falciparum gametocytes detected by microscopy at
baseline. By day 14, this number had decreased to 28/243 (12%)
of patients, with the majority (208/243, 86%) having been treated
with 7 days of artesunate. Nearly one-third of patients (76/243 or
31%) had gametocytes detectable by microscopy at some point
during follow-up.
Molecular detection of Pf gametocytes by RT-PCR for those
patients enrolled in ARC2 showed good concordance with
microscopy (Table S1, Figure 1). All but one patient found to be
gametocytemic at presentation by microscopy were confirmed by
RT-PCR. Additionally, 10 microscopy-negative patients were
positive by RT-PCR. Thus, while 15% (20/136) of ARC2 patients
had smear-detectable gametocytes at baseline, an additional 6%
had subpatent gametocytes identified by RT-PCR.
In the combined data, risk factors associated with baseline
patent gametocytemia by univariate analysis included longer
duration of symptoms, a greater number of malaria episodes in the
previous 12 months, lower baseline hematocrit, lower baseline
temperature, and a higher baseline platelet count (Table S2).
Gametocyte carriage at presentation was also associated with a
faster fever clearance time (median of 5 vs. 18 hrs for those with vs.
without gametocytes).
Post-treatment P. vivax infection
59/243 (24%) patients developed P. vivax infection during
follow-up, 32 by Day 28 in ARC1, and 27 by Day 42 in ARC2
(Table 2, Figure 2). Of these, 20/59 (34%) were febrile or
Table 1. Clinical characteristics of patients by ARC study.
ARC1 2006–7 (n=107) ARC2 2008–9 (n=136) p-value
Age 28 (20–41) 25 (20–35) 0.04
Male gender 68 (64%) 107 (79%) 0.01
History of malaria in previous 12 mos 55 (41%) 45 (33%) 0.01
Duration of symptoms (days) 3 (3–5) 3 (3–4) 0.07
Baseline parasitemia (/ml) 6,562 (2,339–19,849) 12,748 (5,090–34,730) ,0.001*
Baseline parasitemia group
0–10 K 68 (64%) 60 (44%)
10 K–100 K 39 (36%) 69 (51%)
.100 K 0 (0%) 7 (5%)
Baseline temperature (uC) 38.0 (37.2–38.8) 38.1 (37.4–38.9) 0.24
Fever at admission (T.37.9uC) 58 (54%) 77 (57%) 0.71
Baseline hematocrit (%) 38 (33–41) 39 (37–43) 0.01
Presence of Pf gametocytes on admit 23 (22%) 20 (15%) 0.17
Presence of Pf gametocytes on day 14 16 (15%) 12 (9%) 0.14
Presence of Pf gametocytes anytime during follow-up 40 (37%) 36 (26%) 0.07
Parasite clearance time (hrs) 64 (43–91) 78 (60–90) 0.01
Fever clearance time 9 (0–29) 16 (7–29) 0.01
Developed Pv parasitemia during follow-up** 32 (30%) 27 (20%) 0.07
Developed Pv parasitemia by day 28 of follow-up 32 (30%) 15 (11%) ,0.001
Developed Pf recurrence 4 (3.8%) 8 (5.9%) 0.44
Values are reported as median and interquartile ranges unless otherwise specified.
*The difference in baseline parasitemia reflects a difference in the inclusion criteria between the two trials, with no minimum parasitemia required in ARC1.
**Follow-up was for 28 days and 42 days for ARC1 and ARC2, respectively.
doi:10.1371/journal.pone.0018716.t001
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had associated Pv gametocytemia. The median time to the
identification of P. vivax was 28 days in both studies. 55 out of the
59 post-treatment Pv patients had admission blood samples
available for 18 s rRNA PCR analysis. Only 9.1% of these (5/
55) had detectable vivax parasitemia by PCR at Day 0, suggesting
that the majority did not have mixed Pf/Pv blood-stage infection
at presentation that was missed by microscopy (Table 2). When
PCR instead of microscopy was used to identify post-treatment Pv
episodes in the ARC2 patients, the cumulative incidence of Pv
parasitemia did not change, though there were discrepant results
in 8/136 patients (Figure 2, Table S3).
The vivax incidence rate (IR) was calculated to account for the
different durations of follow-up between the two studies. In
ARC1, Pv IR was 331 per 1000 patient months of follow-up.
This was more than double the ARC2 Pv IR of 148 per 1000
patient months of follow-up (Table 2). Just comparing Day 28 Pv
infection rates, 30% (32/107) of patients in ARC1 vs. 11% (27/
136) of patients in ARC2 developed Pv by Day 28 (p,0.001)
(Table 1). Incident rates were similar between the artesunate and
quinine/tetracycline groups in ARC1.
Risk Factors for post-treatment P. vivax infection
On combined univariate analysis, the most prominent risk
factors for the development of post-treatment vivax infection were
the presence of falciparum gametocytes on peripheral smear and a
shorter fever clearance time (Table 3). While the greatest risk was
found in those with baseline Pf gametocytemia by RT-PCR,
gametocytes present at Day 14 or anytime during follow-up were
also associated with a higher rate of post-treatment Pv infection.
In total, of the 43/243 (18%) patients who carried smear-
detectable falciparum gametocytes at admission, nearly half (20/
43, 47%) had a malaria relapse with P. vivax within 28 days
compared to 27/200 (14%) patients without admission Pf
gametocytemia who also relapsed. Those with smear-detectable
baseline gametocytemia demonstrated a 3.5-fold increased inci-
dence rate of vivax malaria post-treatment (IRR=3.5, 95% CI
2.0–6.0, p,0.001) (Table 4). If used as a diagnostic test, the
Figure 1. Detection of baseline falciparum gametocytes by RT-PCR of Pfs25. Gel electrophoresis of Pfs25 transcripts by reverse-
transcriptase PCR from selected patient samples. Patients 014, 149, and 60 were gametocyte-positive by both microscopy and RT-PCR. Patient 145
was negative by both methods. Patient 28 had subpatent gametocytemia detected by PCR only. 3D7 positive control consisted of 1 ng/ml of gDNA
purified from 3D7 Pf erythrocyte culture. Reverse transcriptase-negative controls were done in parallel to ensure there was no DNA contamination of
the purified RNA.
doi:10.1371/journal.pone.0018716.g001
Table 2. Incidence of P. vivax infection following treatment.
No.
Post-treatment
P. vivax
Incidence rate Pv/1000 over
30 days of follow-up
P. vivax detected at
Day 0 by PCR
Median day of onset of P. vivax
following treatment (range)
ARC1 2006–7 107 32 330.7 3/28* (11%) 28 (14–28)
Artesunate 72 21 326.4 2 24 (14–28)
Quinine/tetracycline 35 11 339.2 1 28 (21–28)
ARC2 2008–9
Artesunate** 136 27 147.8 2/27 (7.4%) 28 (21–42)
AS2 72 12 122.7 1 32 (21–42)
AS4 38 7 133.3 0 35 (21–42)
AS6 26 8 246.7 1 25(21–42)
Total combined 243 59 211.1 5/55 (9.1%) 28 (14–42)
*4 Day 0 samples were not available.
**Artesunate was dosed at 2 vs. 4 vs. 6 mg/kg/day67 days.
doi:10.1371/journal.pone.0018716.t002
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with a sensitivity of 47% and a specificity of 87% in our
population. Similar results were also found when the patients with
PCR-detectable P. vivax at admission (n=16) or no baseline
samples available for analysis (n=14) were excluded (IRR=3.7,
95% CI 2.0–6.8, p,0.001), as well as when Pv parasitemia by
Table 3. Comparison of patients with and without P. vivax infection by Day 28 post-treatment.
P. falciparum patients with P. vivax
within 28 days post-treatment (n=47)
P. falciparum patients without
P. vivax (n=196) p-value
Age 27 (22–34) 26 (20–40) 0.52
Male gender 39 (83%) 136 (69%) 0.06
History of malaria in previous 12 mos 26 (55%) 74 (38%) 0.03
Duration of symptoms (days) 3 (3–5) 3 (2–4) 0.16
Baseline parasitemia (/ml) 7,003 (2,903–18,590) 10,093 (4,090–31,770) 0.04
Baseline temperature (uC) 38.0 (37.5–39.0) 38.0 (37.3–38.9) 0.94
Fever at admission (T.37.9uC) 28 (60%) 107 (55%) 0.54
Baseline hematocrit (%) 38 (35–41) 39 (35–42) 0.11
Presence of anemia (Hct,30%) 2 (4.3%) 12 (6.1%) 1.0
Baseline white blood cell count (610
3/ml) 6.5 (4.8–7.7) 5.9 (4.9–7.3) 0.07
Baseline platelet count (610
3/ml) 136 (102–166) 97 (69–135) 0.02
Baseline ALT (alanine aminotransferase U/L)* 18 (14–29) 22 (14–33) 0.42
Presence of Pf gametocytes on admit 20 (43%) 23 (12%) ,0.001
Presence of Pf gametocytes on admit by RT-PCR* 10 (67%) 19 (16%) ,0.001
Presence of Pf gametocytes on day 14 12 (26%) 16 (8.2%) 0.001
Presence of Pf gametocytes anytime during follow up 30 (64%) 46 (23%) ,0.001
Parasite clearance time (hrs) 66 (51–90) 72 (52–90) 0.28
Fever clearance time (hrs) 5 (0–23) 15 (5–29) 0.001
Bioassay positive*,** 0 8 (4.1%) 0.60
Values are reported as median and interquartile ranges unless otherwise specified.
*Data only available for ARC2 patients (Pv n=15, no Pv n=123).
**Antimalarial activity of sera against P. falciparum lab strains in a previously published ex-vivo bioassay, used as a surrogate measure of prior use of antimalarial drugs
[15].
doi:10.1371/journal.pone.0018716.t003
Figure 2. Cumulative proportion of patients with vivax malaria during follow-up based on smear or PCR diagnosis.
doi:10.1371/journal.pone.0018716.g002
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positivity. Finally, the association remained statistically significant
regardless of trial and drug treatment allocation (data not shown).
Other variables associated with post-treatment vivax infection in
the univariate analysis included a history of malaria in the previous
12 months, male gender, a lower baseline parasitemia, and a
higher baseline platelet count.
In the multivariate analysis, each of the major risk factors
identified in univariate analysis as well as other potential
confounding variables, including those that could lead to greater
gametocyte carriage, were adjusted for as covariates. After
removing the bias from these confounding factors, baseline
gametocytemia was associated with a 3.0-fold increased rate of
relapse with vivax malaria (IRR=3.0, 95% CI 1.9–4.7, p,0.001)
(Table 5). Male gender and enrollment in ARC1 were the other
identified independent risk factors for relapse.
Discussion
This analysis uses clinical, microscopic, and molecular data
from two malaria treatment trials conducted in an area co-
endemic for P. falciparum and P. vivax to show that falciparum
gametocytes seen at presentation in patients with P. falciparum
malaria is associated with subsequent relapse with P. vivax malaria.
The finding is robust despite differences in the two study
populations, including a higher Pv incidence rate in ARC1 which
may reflect changing malaria epidemiology in this region. When
baseline subpatent gametocytemia was detected using Pfs25
RT-PCR, the association was strengthened. Gametocyte carriage
continued to be an independent risk factor even after controlling
for potential confounding variables related to exposure and
immunity. Prior inadequate drug treatment is another potential
confounder that may have contributed to high gametocyte
carriage rates in those who relapsed. However, antimalarial use
in the previous 30 days was an exclusion criterion in both studies,
and an ex vivo anti P. falciparum bioassay, conducted on all baseline
ARC2 samples, failed to detect anti-falciparum activity in plasma
Table 4. Comparison of post-treatment vivax incidence rate by risk factor.
Risk present Risk absent
P. vivax
relapse
No P. vivax
relapse
Incidence
rate/1000/
30days
P. vivax
relapse
No P. vivax
relapse
Incidence
rate/
1000/
30days
Risk factor no.
days of
follow-up no.
days of
follow-up no.
days of
follow-up no.
days of
follow-up
Incidence
Rate Ratio 95%CI p value
Male gender 50 1378 125 4662 248 9 244 59 2016 119 2.08 1.01, 4.81 0.03
History of malaria in previous
12 mos
32 881 68 2338 298 27 741 115 4298 161 1.86 1.08, 3.22 0.02
Duration of symptoms .3 days 25 728 55 1946 280 34 894 129 4732 181 1.55 0.88, 2.67 0.10
Baseline parasitemia (/ml) ,10 K 35 937 93 3248 251 24 685 91 3430 175 1.43 0.83, 2.52 0.17
Baseline parasitemia (/ml) .50 K 3 77 24 952 87 56 1545 160 5726 231 0.38 0.08, 1.16 0.07
Fever (T.37.9uC) 31 804 104 3822 201 28 818 80 2856 229 0.88 0.51, 1.52 0.62
Anemia (Hct,30%) 4 133 10 336 256 55 1489 174 6324 211 1.21 0.32, 3.29 0.67
Baseline platelet count ,150 K 14 413 80 3360 111 10 294 18 756 286 0.39 0.16, 0.98 0.03
Abnormal ALT (.40 U/L) 3 70 19 798 104 24 749 88 3696 162 0.64 0.12, 2.11 0.49
Gametocytes on admit 23 609 20 686 533 36 1013 164 5992 154 3.46 1.96, 5.99 ,0.001
Gametocytes on admit by PCR* 16 469 13 546 473 11 350 96 4032 75 6.28 2.74, 15.0 ,0.001
Gametocytes on day 14 14 364 13 420 536 44 1223 171 6258 176 3.04 1.54, 5.64 0.001
Gametocytes anytime during
follow up
39 1071 37 1260 502 20 551 147 5418 101 4.99 2.84, 9.04 ,0.001
Parasite clearance time $72 hrs 25 707 100 3766 168 34 915 84 2912 267 0.63 0.36, 1.09 0.08
Fever clearance time .24 hrs 14 378 74 2716 136 45 1244 109 3934 261 0.52 0.26, 0.97 0.03
Bioassay positive*,** 2 77 6 252 182 25 742 103 4326 148 1.23 0.14, 4.94 0.72
*Data only available for ARC2 patients (Pv n=27, no Pv n=109).
**Antimalarial activity of sera against P. falciparum lab strains in a previously published ex-vivo bioassay, used as a surrogate measure of prior use of antimalarial drugs
[15].
doi:10.1371/journal.pone.0018716.t004
Table 5. Attributable risk of vivax infection post-treatment
after adjusting for covariates*.
Risk factor
Incidence rate
ratio 95%CI p-value
Gametocytes on admit 2.95 1.85 4.69 ,0.001
Enrollment in ARC1 2.10 1.30 3.20 0.002
Male gender 2.41 1.27 4.57 0.007
History of malaria in previous
12 mos
1.46 0.95 2.26 0.074
Fever clearance time .24 hrs 0.70 0.40 1.22 0.434
*Also accounting for confounding from age, parasite density, parasite clearance
time, WBC count, history of malaria, and presence of anemia.
doi:10.1371/journal.pone.0018716.t005
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vivax infection [15].
The low proportion of patients with PCR-detectable Pv at
baseline and the excellent efficacy of the study drugs against Pv
blood stages [3] suggest that most of the post-treatment vivax
infections detected in our study represent reactivation of dormant
hypnozoites rather than recrudescent blood stage Pv parasites not
detected at the time of diagnosis. In addition, post-treatment vivax
infections are unlikely to have resulted from newly inoculated Pv
infections. This is supported by the relatively short follow-up
periods and a relatively low entomological inoculation rate in this
region. Furthermore, patients enrolled in ARC1 stayed in a
structure adjacent to the study ward in the town of Tasanh, a
largely transmission-free area, for 21 of the 28 days of follow-up.
Taken together, these findings suggest that falciparum gameto-
cytes on a blood smear at presentation may be a marker for liver-
stage P. vivax infection in patients with occult mixed infection. We
offer two possible explanations for why this might be the case.
First, the presence of Pf gametocytes may indicate increased
malaria exposure in general and resultant higher levels of acquired
immunity. In this case, patients carrying gametocytes may be more
likely to have acquired a Pv infection in the past and to harbor
hypnozoites in their liver when they are infected with Pf. The
theory that repeated exposure may lead to heightened acquired
immunity and subsequent gametocytemia is supported by previous
in vitro experiments whereby falciparum parasites in culture
displayed increased levels of gametocytogenesis after exposure to
immune Pf sera or anti-Pf antibodies [16]. In our analysis,
gametocytemia was associated with a greater number of previous
episodes of malaria and a faster fever clearance time. Similarly,
male gender was another independent risk factor for Pv relapse,
and men working on the forest fringe in Cambodia are thought to
have the greatest exposure to malaria. However, prior immunity
and exposure do not seem to completely explain the association, as
other plausible markers of immunity, such as a history of malaria
and shorter fever clearance time, were not independently related
to Pv relapse. Gametocytemia remained an important factor even
after controlling for these variables as well as after controlling for
male gender, duration of symptoms, presence of anemia, and
baseline parasite density.
A second explanation is that competition from a second malaria
species may boost falciparum gametocytogenesis as an evolution-
ary adaptation. In this scenario, competition from a second co-
circulating species or immune stress induced by the presence of
another species may induce falciparum parasites to divert from the
asexual to the sexual life cycle, accelerating transmission to new
hosts. This theory is supported by observations from mixed P.
falciparum/P. malariae infections. In a review of Boyd’s early
malariotherapy studies in which neurosyphilis patients were
experimentally inoculated with malaria sporozoites, McKenzie
et al. found that those inoculated with P. falciparum following
P. malariae inoculation developed 3–4 fold higher falciparum
gametocyte densities and gametocytes that appeared 4 days earlier
than in their counterparts with single species P. falciparum infection
[17]. Similarly, in a drug treatment trial (SP+AQ) involving 128
children (aged 6 months to 10 years) in Kenya, the group of 21
children with mixed P. falciparum/P. malariae infection demonstrat-
ed higher gametocyte densities over 28 days with an area under
the curve (AUC) more than twice that of those with P. falciparum
mono-infection [18].
The natural history of mixed infections is characterized by a
pattern of alternating dominance of the two species, where often
only one species is patent despite an underlying mixed infection.
This pattern was evident when Boyd simultaneously inoculated
two malaria-naı ¨ve patients with P. falciparum and P. vivax
sporozoites and followed daily blood smears [19,20]. It has also
been seen more recently in the field setting among asymptomatic
semi-immune children in Papua New Guinea [21]. In light of
these observations, we hypothesize that, prior to presentation,
patients who went on to develop Pv were originally inoculated
with a mixed Pf/Pv infection in which co-circulating Pv parasites
induced gametocytogenesis in their Pf counterparts. These blood-
stage Pv parasites may have subsequently been ‘‘outcompeted’’ by
the dominant Pf infection such that by the time the patient
presented with symptomatic asexual Pf parasitemia, the only
evidence of prior Pv infection were hypnozoites in the liver and
circulating falciparum gametocytes.
Alternatively, these results could lead to the conclusion that
falciparum gametocytes directly trigger reactivation of vivax
hypnozoites in the liver. However, in the Myanmar ACT study,
a single dose of primaquine, which was very effective at decreasing
post-treatment gametocyte carriage, did not seem to have an effect
on the post-treatment Pv incidence rate [8]. Similarly, while our
artesunate-treated patients had lower rates of post-treatment
gametocyte carriage than those treated with quinine plus
tetracycline, the two treatment groups relapsed with vivax malaria
at a similar rate. We also did not find any relationship between
gametocyte density and the risk of 28-day relapse, or timing of
gametocyte appearance and time to Pv relapse.
A recent study by Douglas et al., based on 15 years of clinical
trial data from the Thai-Burmese border, reports a similar
association in falciparum-infected patients who relapsed with
vivax malaria. Though the reported effect size was smaller (AHR
1.4, 95%CI 1.1–1.7), those with Pf gametocytemia at enrollment
still represented the single group with the highest risk of Pv
recurrence (41% by day 63) according to baseline risk factors [9].
Confirmatory findings should be sought in other regions with
mixed species Plasmodium infections as well.
Our study adds to the literature by providing insights into the
pathophysiology of relapse in patients with occult Pf/Pv infection
in southeast Asia and identifying an easily distinguished marker
for patients with falciparum malaria who are at risk for vivax
relapse. Recognizing the high likelihood of occult P. vivax
coinfection in gametocytemic individuals further highlights the
potential public health gains that could be achieved with more
widespread G6PD testing [22]. In areas where G6PD testing is
currently available, our results suggest that treating gametocy-
temic patients with a full course of primaquine may reduce the
proportion of patients with vivax relapse. Such an approach
could stratify the risk of G6PD related hemolysis, reserving
presumptive full course primaquine treatment for those at a
higher risk of relapse. In our study area, adopting such a strategy
would target ,18% of patients while potentially preventing up to
39%, i.e. the population attributable fraction, of early vivax
relapses. In Thailand, falciparum-infected patients are already
given one dose of primaquine with an ACT to target gametocytes
as part of a transmission-blocking strategy. In the midst of
malaria elimination efforts on the Thai-Cambodian border,
failure to offer a full course of primaquine to falciparum patients
with gametocytes could represent a missed opportunity to also
reduce rates of P. vivax malaria, arguably the harder species to
eliminate because of its propensity for relapse.
In summary, in Cambodian patients with acute falciparum
malaria, the presence of P. falciparum gametocytes on blood smear
at presentation is associated with subsequent P. vivax relapse; this
has important implications for malaria treatment and control
strategies in settings where mixed P. falciparum/P. vivax infections
are common.
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